NOXOPHARM

A clinical-stage oncology drug company developing a disruptive technology for the treatment of solid cancers by radiotherapy and chemotherapy

Open Briefing June 2018

Unique dual-acting anti-cancer drug

NOX66 **Idronoxil (lipophilic form)**



inhibits DNA repair

inhibits PARP-1, topoisomerases 1 and 2



promotes anti-tumour immunity

Increases NK (natural killer) cell activity

3-horse race

- Risk mitigation
- Identify optimal route to market
- Expand post-registration markets

CEP

DARRT

LuPIN

CEP

NOXOPHARM

Chemotherapy Enhancement Program

Objective:

- To enable salvage chemotherapy in patients with late-stage, resistant cancers
- NOX66 in combination with low-dose cytotoxic chemotherapy
- Aim to deliver a meaningful anti-cancer effect
  in at least 50% patients
  in a well tolerated way

CEP

NOXOPHARM

CEP-1 Phase 1 Sighting study

Details:

- 19 patients; late-stage, metastatic cancer; no remaining standard Rx options
- Breast, lung, ovarian, prostate
- 14-day NOX66 run-in
- 6 cycles; each cycle = NOX66 (7 days) + carboplatin (1 day) each month
- 3 patients withdrew voluntarily; 1 carboplatin sensitivity; 1 sudden death; 4 death from progressive disease; 2 non-evaluable

CEP

CEP-1

Outcomes

Safety:

- 5 Grade 3 toxicities, all resolved. All other toxicities mild.
- No toxicity associated with NOX66

Efficacy:

	Partial response	Stable disease	Disease progression	Total
3 cycles	0	12	2	14
6 cycles	1	5	4	10*

* 12 started: 1 withdrew: 1 sudden death

CEP

CEP-2

- Phase 2
- NOX66 Dosage: 800 mg
- Platinum based therapy. Which drug?
  - Carboplatin
  - Cisplatin
  - Oxaliplatin
- Which cancer type(s)? What end-points?
- Protocol design
  - Q3 Meet with Advisory Board
  - Q4 Final protocol
  - Early-2019 Study opens

DARRT

Direct and Abscopal Response to Radio-Therapy

External Beam RT or Stereotactic Body RT

- Patients with multiple (>3) tumours
- Irradiate 1-2 tumours (5 days)
- NOX66 14 days
- Scan + 6 weeks and 12 weeks



DARRT

Direct and Abscopal Response to Radio-Therapy

NOXOPHARM

Direct Response



Radiotherapy applied to large tumours for pain relief



Shrinkage of irradiated tumours

NOX66



Seeking complete remission of irradiated tumours

DARRT

Direct and Abscopal Response to Radio-Therapy

NOXOPHARM

Abscopal Response



Low-dose radiotherapy



Seeking complete remission of irradiated tumours

NOX66



Abscopal response

DARRT

DARRT-1

Details:

- Phase 1b multi-national study
- 24 patients; metastatic castrate-resistant prostate cancer
- NOX66 + External beam RT
- RT (5-10 days) ▲ NOX66 (duration of RT + 7 days)
- 4 Cohorts:
  - 400 mg NOX66 (4 patients) ***completed***
  - 800 mg NOX66 (4 patients) ***completed***
  - 1200 mg NOX66 (4 patients) ***enrolled***
  - Best NOX66 dose (12 patients)

DARRT

DARRT-1

SCHEDULE

- Late-July 2018. Complete treatment and 6-week scans on first 3 cohorts.
  - Independent review of data
  - Select NOX66 dosage

- Late-Aug 2018. Commence recruitment of Cohort 4.
  - Target complete recruitment of all 24 patients in Q3 2018
  - 12 week review for all patients Q4
  - Study complete Q1 2019

DATA RELEASE

- Early-July 2018. Presentation at ANZUP
  - Study outline, safety of initial treatment

- Aug 2018. Release of 6-week data.

DARRT

Other Studies

- DARRT-2: Solid tumours
  - Phase 1b; expanding DARRT-1 research beyond prostate cancer
  - Provide guidance on criteria which may suggest better response to NOX66
  - Decision point – DARRT-1: 12 patient, 6 weeks scan → drive protocol development
  - Commence study Q4 2018
- DARRT-3: Phase 2/3 registrational planning
  - Key study for first registration of NOX66
  - Feasibility, country and site identification (global) commence Q3 2018
  - Decision point – DARRT-1: 24 patients, 12 week → submission processes begin
  - Commence mid 2019
- Supportive research
  - Further small investigator led research studies
    - Specific patient populations; treatment regimen (e.g. stereotactic RT)

LuPIN

Lutetium-PSMA In Combination With NOX66

NOXOPHARM



THERANOSTICS



LuPIN

Lutetium-PSMA In Combination With NOX66



THERANOSTICS

- Phase 1b study; investigator-initiated; St Vincent's Hospital Sydney
- Late-stage prostate cancer (metastatic castrate-resistant disease)
- ^{177} Lutetium-PSMA-617
- 6 x monthly intravenous injections of LuPSMA + 10 days NOX66
- 6 patients 400 mg NOX66; 10 patients 800 mg NOX66

LUPIN

Lutetium-PSMA In Combination With NOX66

- ❖ LuPIN-1
  - Recruitment ongoing – presentation of trial outline at ASCO 2018
  - First 4 patients in 5th cycle of therapy; first key data expected late-2018
- ❖ Next Steps
  - Development of expanded LuPIN study
    - Phase 2 multi-centre, sponsored study
    - Planned commencement early-2019
  - Other targeted radionuclides
    - Partnership planning for other targeted therapies
    - Phase 1 studies early-2019

Key metrics .....

Number of Shares	**121.9M** : Free float 66.8%
Market Cap (6.6.2018)	$90M
IPO price	20 cents
12 month high/low	$1.58/0.29
Average daily turnover	$0.54M
Cash position	AU$ 11.8 (31 March 2018)



Disclaimer

- This presentation has been prepared by Noxopharm Limited a company proposed to be listed as [ASX:NOX] (NOX or the Company). It should not be considered as an offer or invitation to subscribe for or purchase any shares in NOX or as an inducement to make an offer or invitation to subscribe for or purchase any shares in NOX. No agreement to subscribe for securities in the NOX will be entered into on the basis of this presentation or any information, opinions or conclusions expressed in the course of this presentation.
- This presentation is not a prospectus, product disclosure document or other offering document under Australian law or under the law of any other jurisdiction. It has been prepared for information purposes only. This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of an individual investor. It is not a financial product advice and the Company is not licenced to, and does not provide, financial advice.
- This presentation may contain forward-looking statements which are identified by words such as 'may', 'could', 'believes', 'estimates', 'targets', 'expects', or 'intends' and other similar words that involve risks and uncertainties. These statements are based on an assessment of past and present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors many of which are beyond the control of the Company, its Directors and management.
- Although the Company believes that the expectations reflected in the forward looking statements included in this presentation are reasonable, none of the Company, its Directors or officers can give, or gives, any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this document will actually occur or that the assumptions on which those statements are based are exhaustive or will prove to be correct beyond the date of its making. Readers are cautioned not to place undue reliance on these forward-looking statements. Except to the extent required by law, the Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation.
- Readers should make their own independent assessment of the information and take their own independent professional advice in relation to the information and any proposed action to be taken on the basis of the information. To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates and each of their respective directors, officers, management, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation and liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use of or reliance on anything contained in, or omitted from, this presentation. Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after the date of this presentation document which may affect any matter referred to in the presentation.

NOXOPHARM